Zenas BioPharma (ZBIO) shares collapsed by more than 50% in the most recent trading session after the company released Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD). The trial showed a meaningful reduction in flare risk, which sounds like good news. But efficacy metrics fell short of what the market was hoping for, and the stock got hammered.

Here's the thing though: if you were watching the stock through the lens of the Adhishthana framework, this wasn't exactly a bolt from the blue. The cyclical positioning had already been flashing warning signs about elevated risk. Understanding why the selloff was so aggressive and what comes next requires looking at the structural setup beneath the surface.

Reading the Adhishthana Structure

On the weekly charts, Zenas is currently sitting in Phase 2 of its 18-phase Adhishthana cycle. Phase 2 breaks down into two segments. First comes the Sankhya period, which typically brings consolidation, volatility, or outright bearish pressure. After that, you get the Buddhi period, when stocks often deliver sustained, structurally supported rallies.

But Zenas didn't follow the script. Instead of consolidating during Sankhya, the stock rallied sharply right out of the gate. That's a deviation from the expected pattern, and historically, rallies that show up early during Sankhya tend to be fragile. They look good until reality catches up, and then they get corrected fast.

That's exactly what happened here. The market punished the deviation, and we've seen similar setups play out in other high-volatility biotech names where early optimism gives way to abrupt collapses once expectations reset.

Should You Buy the Dip?

After a 50% drop, the natural question is whether the stock looks attractive now. The short answer: probably not yet. Zenas is still firmly within its Sankhya period and hasn't transitioned into the Buddhi phase. Until that happens, expect volatility to remain elevated and directional clarity to stay limited.

There's another wrinkle. Deviations during Phase 2 often damage the quality of any subsequent Buddhi move. In some cases, the anticipated sustained rally never materializes at all. That supports a wait-and-watch approach rather than trying to catch a falling knife after a sharp drawdown.

It's also worth noting that Phase 2 deviations frequently point to latent structural risks that don't show up in the fundamentals right away. The recent downgrade from Morgan Stanley aligns with this broader deterioration in the stock's risk profile, adding another layer of caution.

What Investors Should Watch For

Sharp rallies followed by equally sharp collapses aren't unusual in early-stage biotech stocks. Similar patterns have played out in names like uniQure, where sudden optimism was followed by overnight losses exceeding 50%. In fact, hidden risks in that setup were flagged shortly before the breakdown occurred.

Zenas BioPharma appears to be following a comparable path. Adding to the complexity, the stock also remains in Phase 1 on the monthly charts, a phase known for heightened volatility. That means investors need to maintain high risk tolerance if they're playing in this space.

For now, increasing exposure feels premature. A more prudent approach would be to wait for the stock to transition into the Buddhi phase, where volatility typically subsides and structural clarity improves. Until that transition happens, the risks associated with the current setup outweigh the potential reward.

The recent collapse may look extreme on the surface, but within the Adhishthana framework, it reflects a breakdown that had been building structurally beneath the surface all along. Sometimes the market moves that seem most shocking are actually the ones that make the most sense when you know where to look.